Navigation Links
Canadian scientist develops world's most advanced drug to protect the brain after a stroke
Date:2/29/2012

Toronto, February 29, 2012 - Scientists at the Toronto Western Research Institute (TWRI), Krembil Neuroscience Center, have developed a drug that protects the brain against the damaging effects of a stroke in a lab setting. This drug has been in development for a few years. At this point, it has reached the most advanced stage of development among drugs created to reduce the brain's vulnerability to stroke damage (termed a "neuroprotectant"). Over 1000 attempts to develop such drugs by scientists worldwide have failed to be translated to a stage where they can be used in humans, leaving a major unmet need for stroke treatment. The drug developed by the TWRI team is the first to achieve a neuroprotective effect in the complex brain of primates, in settings that simulate those of human strokes. ischemic stroke.

The study, "Treatment of Stroke with a PSD95 inhibitor in the Gyrencephalic Primate Brain", published online today in Nature, shows how the drug, called a "PSD95 inhibitor" prevents brain cell death and preserves brain function when administered after a stroke has occurred.

"We are closer to having a treatment for stroke than we have ever been before," said Dr. Michael Tymianski, TWRI Senior Scientist and the study's lead author. "Stroke is the leading cause of death and disability worldwide and we believe that we now have a way to dramatically reduce its damaging effects."

During a stroke, regions of the brain are deprived of blood and oxygen. This causes a complex sequence of chemical reactions in the brain, which can result in neurological impairment or death. The PSD95 inhibitor published by the Toronto team acts to protect the brain by preventing the occurrence of these neurotoxic reactions.

The study used cynomolgus macaques, which bear genetic, anatomic and behaviour similarities to humans, as an ideal model to determine if this therapy would be beneficial in patients.

Animals that were treated wi
'/>"/>

Contact: Nadia Daniell-Colarossi
nadia.daniell-colarossi@uhn.on.ca
416-603-5294
University Health Network
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Canadian Isotope Project enters final stretch
2. 1 in 10 Canadians cannot afford prescription drugs: UBC study
3. Warwick joins $3.4 million Anglo-Canadian quest for new weapons in war against antibiotic resistance
4. New Canadian Guidelines Also Support No Routine Mammograms Until 50
5. Canadian breast cancer screening guidelines would cost thousands of lives
6. Canadian Diabetes Association announces Elsevier as new publisher of Canadian Journal of Diabetes
7. Canadian researchers find potential new leukemia treatment with old antibiotic drug
8. Heart transplant surgery safe and effective: A Canadian retrospective spanning 3 decades
9. Canadian Journal of Cardiology publishes report on delayed vs. immediate coronary stenting
10. How hemp got high: Canadian scientists map the cannabis genome
11. Fatal crashes in the US: Fewer Canadian drivers under the influence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... September 30, 2014 World of Children ... founder of the nonprofit, Friends Without A Border (FWAB) ... for building a hospital in Cambodia that has become ... Izu first encountered Cambodia’s appalling lack of pediatric healthcare ... disabilities and illnesses during a photography trip in 1993. ...
(Date:9/30/2014)... 30, 2014 During this online ... approaches to health including achieving hormonal balance, relieving ... and detoxification. , The details ... Date: October 6-9, 2014, Location: Online Event, Registration: ... http://www2.hotzehwc.com/naturalhealthsummitregistration , Monday, October 6th, Steven F. ...
(Date:9/30/2014)... September 30, 2014 AutoTex PINK ... the iconic pink ribbon in support of breast cancer ... month for businesses and non-profits to “go pink” -- ... , AutoTex PINK is a woman-owned company that is ... They are committed to partnering with their customers to ...
(Date:9/30/2014)... September 30, 2014 Timber Home Living Magazine ... for the Olsen family’s reclaimed Douglas fir timber frame home ... home’s journey from architectural planning, to the frame raising, to ... to New Energy Works, after following the timber framing company ... build their dream vacation home on land they fell in ...
(Date:9/30/2014)... Oxnard, CA (PRWEB) September 30, 2014 ... the Anacapa Dental Art Institute in Oxnard and Thousand ... Bangalore today and tomorrow to provide training on full ... previous dental work, placing implants, providing cosmetic dentistry, correcting ... Dr. Jivraj said. , Dr. Jivraj, who has traveled ...
Breaking Medicine News(10 mins):Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 2Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 3Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 2Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5
... 27 (HealthDay News) -- Arizona Congresswoman Gabrielle Giffords began ... forward for the lawmaker who was shot in the ... Memorial Hermann Hospital could last several months. As a ... insert a valve into her breathing tube, the ...
... January 27, 2011 Screening patients in the intensive ... cost savings for the whole hospital, according to a ... the February issue of the American Journal of ... the Association for Professionals in Infection Control and Epidemiology. ...
... , THURSDAY, Jan. 27 (HealthDay News) -- Only 42 ... and can therefore be categorized as "great sleepers," according to ... Poll" found that great sleepers get an average of about ... sleeper gets an average of seven hours and nine minutes ...
... News) -- Electroshock devices, currently classified by the U.S. Food ... severe depression, could be downgraded to medium risk this year. ... to discuss reclassifying the devices, which would pave the way ... illnesses. , , A medium-risk classification would put the devices ...
... continue dating a girlfriend who has cheated on them with ... according to new research from a University of Texas at ... are more likely to continue dating a man who has ... homosexual affair. The study, published last month in the ...
... in China have demonstrated interferon-alpha (IFN-a) is associated with ... erythematosus (SLE). For the first time, IFN-a priming was ... crucial step in plaque build-up. This activation of the ... atherosclerosis risk in SLE. Full findings of this novel ...
Cached Medicine News:Health News:Rep. Giffords' Intensive Rehab Under Way 2Health News:Rep. Giffords' Intensive Rehab Under Way 3Health News:Study finds MRSA screening saves hospitals money 2Health News:Loving Your Bedroom May Be Key to Good Sleep 2Health News:FDA May Ease Up on Electroshock Devices 2Health News:FDA May Ease Up on Electroshock Devices 3Health News:Men more likely to stick with girlfriends who sleep with other women than other men 2Health News:Researchers uncover link to increased atherosclerosis risk in lupus patients 2
(Date:9/30/2014)... , Sept. 30, 2014 CytRx Corporation ... and development company specializing in oncology, today announced ... trial evaluating aldoxorubicin compared to topotecan in subjects ... have relapsed or were refractory to prior chemotherapy. ... chemotherapeutic agent, doxorubicin. CytRx has received Orphan Drug ...
(Date:9/29/2014)... and PARIS , Sept. ... and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced ... investigational therapy that blocks IL-4 and IL-13 signaling, met ... chronic sinusitis with nasal polyps (CSwNP) who did not ... suggest the potential of dupilumab for use in the ...
(Date:9/29/2014)... et SAN DIEGO , ... Ltd. (ci-après désignée Daiichi Sankyo) (TSE : 4568) et ... la conclusion d,un accord de fusion définitif en ... totalité des actions ordinaires en circulation d,Ambit Biosciences ... le biais d,une offre publique d,achat qui sera ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 2Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 3Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 4Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 6Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 7Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
Used with T-tubes to collect drainage after cholecystectomy. Includes T-tube adapter and two adjustable latex rubber belts....
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Silicone Flat Hubless Drains...
Bard® Channel Drain...
Medicine Products: